Trial Profile
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Interferon beta-1b
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SWABIMS
- 01 Nov 2012 Primary endpoint 'Magnetic-resonance-imaging-outcomes' has not been met.
- 06 Sep 2011 Actual start date of the extension trial is March 2007 according to ClinicalTrials.gov (extension trial: NCT01111656).
- 06 Sep 2011 Actual completion date of the extension trial is Apr 2010 according to ClinicalTrials.gov (extension trial: NCT01111656).